Clinical Trial

Zemaira Eosinophilic Esophagitis Pilot Study

Study acronym: ZEEPS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2022-08-01; most recent amendment 2025-12-16.
Status change: Not Yet Recruiting → Recruiting 2023-06-20
Trial Details
NCT Number NCT05485155
Lead Sponsor Children's Hospital Medical Center, Cincinnati
Collaborators: CSL Behring, National Institutes of Health (NIH)
Conditions Eosinophilic Esophagitis
Enrollment 15 participants
Start Date 2025-05-15
Primary Completion 2026-10 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-17